Promega, J1191, PD-1/PD-L1 Blockade Bioassay

Immune Checkpoint Bioassays for Characterizing Immune-Modulating Antibodies
Prequalified according to ICH guidelines
96- and 384-well plate formats
No primary cell culture required
Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Specifications：
PD-1 Effector Cells J115A 1 × 0.5ml
PD-L1 aAPC/CHO-K1 Cells J109A 1 × 0.5ml
Fetal Bovine Serum J121A 1 × 4ml
Ham's F-12 Medium J123A 1 × 25ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
PD-1 Effector Cells J115A 5 × 0.5ml
PD-L1 aAPC/CHO-K1 Cells J109A 5 × 0.5ml
Fetal Bovine Serum J121A 5 × 4ml
Ham's F-12 Medium J123A 5 × 25ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
PD-1 Effector Cells (CPM) J112A 2 × 1ml
PD-L1 aAPC/CHO-K1 Cells (CPM) J108A 2 × 1ml
aAPC/CHO-K1 Cells J119A 1 × 0.5ml
aAPC/CHO-K1 Cells J119A 5 × 0.5ml
Control Ab, Anti-PD-1 J120A 1 × 100μg
PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of PD-1 by either of its ligands, PD-L1 or PD-L2, on an adjacent cell inhibits TCR signaling and TCR-mediated proliferation, transcriptional activation and cytokine production. Therapeutic antibodies and Fc fusion proteins designed to block the PD-1/PD-L1 interaction show promising results in clinical trials for the treatment of a variety of cancers.
The PD-1/PD-L1 Blockade Bioassay is a biologically relevant MOA-based assay that can be used to measure the potency and stability of antibodies and other biologics designed to block the PD-1/PD-L1 interaction.
Control Ab, Anti-PD-1, is a mouse anti-human PD-1 antibody that shows blocking activity for PD-1 with its ligands PD-L1 and PD-L2. It is intended for use as a control with the PD-1/PD-L1 Blockade Bioassay.
aAPC/CHO-K1 Cells are CHO-K1 cells with an engineered cell surface protein designed to activate cognate TCRs in an antigen-independent manner. The PD-L1 Negative aAPC/CHO-K1 Cells can serve as a negative control in the PD-1/PD-L1 Blockade Bioassay.